

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: HANSSON, Lennart
 Serial No.: 10/071,214
 Filed: February 11, 2002
 For: SCCE MODIFIED TRANSGENIC MAMMALS AND THEIR USE AS...
 Confirmation No.: 9275

Art Unit: 1632
 Examiner: BERTOGLIO, V.
 Washington, D.C.
 Atty.'s Docket: HANSSON=3A
 Date: July 8, 2003



RECEIVED
 JUL 15 2003
 TECH CENTER 1600/2900

U.S. Patent and Trademark Office
 2011 South Clark Place
 Customer Window
 Crystal Plaza Two, Lobby, Room 1B03
 Arlington, Virginia 22202

Sir:
 Transmitted herewith is an [XX] Amendment [XX] English translation of the claims of Ref. AF
 in the above-identified application.

- [] Small entity status of this application under 37 CFR 1.9 and 1.27 has been established by a verified statement previously submitted.
 [XX] Small entity status of this application under 37 CFR 1.9 and 1.27 has been previously asserted.
 [] A verified statement to establish small entity status under 37 CFR 1.9 and 1.27 is enclosed.

The fee has been calculated as shown below:

(Col. 1)		(Col. 2)		(Col. 3)		Small Entity		Other Than a Small Entity	
	Claims Remaining After Amendment		Highest No. Previously Paid For		Present Extra		Rate		Additional Fee
Total	64	Minus	58	6		x 9	\$54.00	x18	\$
Indep.	6	Minus	5	1		x42	\$42.00	x84	\$
First Presentation of Multiple Dependent Claim						140	\$	+280	\$
TOTAL ADDITIONAL CLAIMS FEE							\$96.00	Total	\$

- * If the entry in Col. 1 is less than the entry in Col. 2, write "0" in Col. 3.
 ** If the "Highest Number Previously Paid For" IN THIS SPACE is less than 20, write "20" in this space.
 *** If the "Highest Number Previously Paid For" IN THIS SPACE is less than 3, write "3" in this space.
 The "Highest Number Previously Paid For" (total or independent) is the highest number found from the equivalent box in Col.1 of a prior amendment of the number of claims originally filed.

[XX] Conditional Petition for Extension of Time
 If any extension of time for a response is required applicant requests that this be considered a petit

[XX] It is hereby petitioned for an extension of time in accordance with 37 CFR 1.136(a). The appropriate fee required by 37 CFR 1.17 is calculated as shown below:

Small Entity		Other Than Small Entity	
Response Filed Within		Response Filed Within	
[] First	- \$ 55.00	[] First	- \$ 110.00
[XX] Second	- \$205.00	[] Second	- \$ 410.00
[] Third	- \$465.00	[] Third	- \$ 930.00
[] Fourth	- \$725.00	[] Fourth	- \$1450.00
[] Fifth	- \$985.00	[] Fifth	- \$1970.00

[] Less fees (\$) already paid for months extension of time on

[] Please charge my Deposit Account No. 02-4035 in the amount of \$. A duplicate copy of this sheet is attached.

[] A check in the amount of \$ is attached (check no.).

[XX] Credit Card Payment Form, PTO-2038, authorizing payment in the amount of \$301.00 is attached.

[XX] The Commissioner is hereby authorized and requested to charge any additional fees which may be required in connection with this application or credit any overpayment to Deposit Account No. 02-4035. This authorization and request is not limited to payment of all fees associated with this communication, including any Extension of time fee, not covered by check or specific authorization, but is also intended to include all fees for the presentation of extra claims under 37 CFR Section 1.16 and all patent processing fees under 37 CFR Section 1.17 throughout the prosecution of the case. This blanket authorization does not include patent issue fees under 37 CFR Section 1.18.

BROWDY AND NEIMARK, P.L.L.C.
 Attorneys for Applicant(s)

Facsimile: (202) 737-3528
 Telephone: (202) 628-5197

By:
 DAVID P. COOPER
 Registration No. 28,005



#1313
7/26/03
RECEIVED
JUL 15 2003
TECH CENTER 1600/2800

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:) Art Unit: 1632
HANSSON, Lennart) Examiner: BERTOGLIO, V.
Serial No.: 10/071,214) Washington, D.C.
Filed: February 11, 2002) July 8, 2003
For: SCCE MODIFIED TRANSGENIC) Docket No.: HANSSON=3A
MAMMALS AND THEIR USE AS) Confirmation No.: 9275
MODELS OF HUMAN DISEASES)

AMENDMENT UNDER RULE 1.115

U.S. Patent and Trademark Office 07/10/2003 SZEWDIE1 00000069 10071214
2011 South Clark Place 01 FC:2201 42.00 OP
Customer Window 02 FC:2202 54.00 OP
Crystal Plaza Two, Lobby, Room 1B03
Arlington, Virginia 22202

S i r :

In response to the office action mailed February 13, 2003, please enter the following amendments and remarks.

Adjustment date: 07/11/2003 SZEWDIE1
07/10/2003 SZEWDIE1 00000069 10071214
03 FC:2252 -201.00 OP

IN THE SPECIFICATION

Please amend the specification to read as follows:

Paragraph beginning at line 24 of page 18 has been amended as follows:

B¹
Preferably, the transgenic mammal or mammalian embryo according to the invention comprises a heterologous nucleotide sequence comprising a significant part of DNA sequence coding for human SCCE as shown in SEQ ID NO:1. The transgenic mammal or mammalian embryo according to the invention preferably comprises a nucleotide sequence coding for a significant part of the peptide shown in SEQ ID NO. 2 as defined above. In preferred embodiments, the DNA sequence codes for the peptide corresponding to amino acid no. -7 through no. 224 of human SCCE (with the first AA of active human SCCE numbered "1"), which corresponds to AAs 23-253 of the amino acid sequence shown in SEQ ID NO. 2; the peptide corresponding to amino acid no. 1 through no. 224 of

07/11/2003 SZEWDIE1 00000107 024035 10071214

01 FC:2252 4.00 DA 201.00 OP

~~07/10/2003 SZEWDIE1 00000069 10071214~~

~~03 FC:2252~~

~~-201.00 OP~~